Nevro (NVRO) Earning Somewhat Positive News Coverage, Study Shows
News coverage about Nevro (NYSE:NVRO) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nevro earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 47.1603826315735 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities analysts recently commented on the stock. BidaskClub lowered shares of Nevro from a “hold” rating to a “sell” rating in a research report on Saturday, October 28th. TheStreet raised shares of Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. ValuEngine lowered shares of Nevro from a “hold” rating to a “sell” rating in a research report on Friday. BMO Capital Markets reaffirmed a “buy” rating and set a $100.00 price target on shares of Nevro in a research report on Thursday, December 14th. Finally, Northland Securities reaffirmed a “buy” rating and set a $96.00 price target on shares of Nevro in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $99.25.
Nevro (NYSE NVRO) traded up $2.07 during mid-day trading on Tuesday, reaching $77.07. 547,496 shares of the company’s stock traded hands, compared to its average volume of 415,007. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59. Nevro has a 52-week low of $65.00 and a 52-week high of $99.63. The company has a market cap of $2,280.00, a price-to-earnings ratio of -53.15 and a beta of -0.59.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 9.10% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/02/07/nevro-nvro-earning-somewhat-positive-news-coverage-study-shows.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.